Trovagene Inc. Daily Stock Analysis

Daily Stock Analysis, TROV, Trovagene Inc, priceseries

Trovagene Inc. Daily Stock Analysis
Stock Information
Open
13.81
Close
12.02
High
14.08
Low
12.02
Previous Close
13.34
Daily Price Gain
-1.32
YTD High
977.76
YTD High Date
Jun 12, 2015
YTD Low
0.70
YTD Low Date
Mar 19, 2020
YTD Price Change
-316.30
YTD Gain
-96.34%
52 Week High
977.76
52 Week High Date
Jun 12, 2015
52 Week Low
0.70
52 Week Low Date
Mar 19, 2020
52 Week Price Change
-316.30
52 Week Gain
-96.34%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 13. 2017
74.88
Apr 17. 2017
81.36
1 Trading Days
8.65%
Link
LONG
Jun 21. 2017
68.14
Jul 6. 2017
78.73
10 Trading Days
15.54%
Link
LONG
Feb 2. 2018
21.38
Feb 15. 2018
24.33
9 Trading Days
13.83%
Link
LONG
Mar 9. 2018
25.99
Mar 15. 2018
27.83
4 Trading Days
7.06%
Link
LONG
Jun 5. 2019
3.03
Jun 7. 2019
3.25
2 Trading Days
7.10%
Link
LONG
Aug 16. 2019
2.09
Aug 21. 2019
2.28
3 Trading Days
9.21%
Link
LONG
Oct 24. 2019
2.24
Oct 25. 2019
2.45
1 Trading Days
9.15%
Link
LONG
Jan 17. 2020
1.38
Jan 29. 2020
1.66
7 Trading Days
20.63%
Link
LONG
Apr 22. 2020
0.93
May 8. 2020
1.10
12 Trading Days
17.89%
Link
LONG
May 14. 2020
1.43
Jun 9. 2020
2.77
17 Trading Days
93.60%
Link
LONG
Jun 18. 2020
2.95
Jul 2. 2020
4.39
10 Trading Days
48.82%
Link
LONG
Jul 30. 2020
4.60
Aug 12. 2020
5.45
9 Trading Days
18.52%
Link
LONG
Aug 19. 2020
6.66
Sep 3. 2020
7.12
11 Trading Days
6.89%
Link
LONG
Sep 17. 2020
8.11
Oct 15. 2020
15.01
20 Trading Days
85.04%
Link
Company Information
Stock Symbol
TROV
Exchange
NasdaqCM
Company URL
http://www.trovagene.com
Company Phone
858-217-5420
CEO
Bill Welch
Headquarters
California
Business Address
11055 FLINTKOTE AVENUE, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Laboratories & Research
CIK
0001213037
About

Trovagene, Inc. is a molecular diagnostic company, which focuses on the development and commercialization of a proprietary urine-based molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.

Description

Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research, and medical testing in various clinical disciplines in the United States. The company intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor circulating tumor DNA (ctDNA) using urine or blood samples. It offers Precision Cancer Monitoring (PCM) platform, which provides cancer monitoring by tracking and quantifying levels of ctDNA from either urine or blood samples, as well as intends to offer clinical information beyond the current standard of care. The company also provides assays for the BRAF, KRAS, and epidermal growth factor receptor oncogenes; and engages in developing mutation coverage for other cancers, such as lung and colorectal cancers, as well as targeting clinically validated resistance mutations for gene rearrangements, including ALK, RET, and ROS. In addition, it offers laboratory developed tests for pharmaceutical companies and third party laboratories. The company has a license agreement with Nerviano Medical Sciences to develop and commercialize therapeutic candidate PCM-075. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading